ShockWave Medical, Inc. (SWAV)
NASDAQ: SWAV · IEX Real-Time Price · USD
330.00
+1.01 (0.31%)
At close: Apr 26, 2024, 4:00 PM
326.89
-3.11 (-0.94%)
After-hours: Apr 26, 2024, 4:06 PM EDT
ShockWave Medical Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for ShockWave Medical stock have an average target of 287.11, with a low estimate of 165 and a high estimate of 360. The average target predicts a decrease of -13.00% from the current stock price of 330.00.
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for SWAV stock from 12 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 0 |
| Buy | 4 | 3 | 3 | 3 | 3 | 1 |
| Hold | 3 | 3 | 3 | 3 | 3 | 10 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 12 | 12 | 12 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| CL King | CL King | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Apr 8, 2024 |
| Leerink Partners | Leerink Partners | Buy → Hold Downgrades $361 → $335 | Buy → Hold | Downgrades | $361 → $335 | +1.52% | Apr 8, 2024 |
| Deutsche Bank | Deutsche Bank | Strong Buy → Hold Downgrades $270 → $335 | Strong Buy → Hold | Downgrades | $270 → $335 | +1.52% | Apr 8, 2024 |
| Morgan Stanley | Morgan Stanley | Buy → Hold Downgrades $285 → $335 | Buy → Hold | Downgrades | $285 → $335 | +1.52% | Apr 8, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy → Hold Downgrades $263 → $335 | Strong Buy → Hold | Downgrades | $263 → $335 | +1.52% | Apr 5, 2024 |
Financial Forecast
Revenue This Year
939.30M
from 730.23M
Increased by 28.63%
Revenue Next Year
1.16B
from 939.30M
Increased by 22.96%
EPS This Year
4.95
from 3.85
Increased by 28.54%
EPS Next Year
6.30
from 4.95
Increased by 27.39%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 971.3M | 1.2B | 1.5B | 1.8B | 1.9B |
| Avg | 939.3M | 1.2B | 1.4B | 1.6B | 1.9B |
| Low | 899.1M | 1.1B | 1.2B | 1.4B | 1.8B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 33.0% | 31.3% | 30.8% | 32.6% | 21.0% |
| Avg | 28.6% | 23.0% | 19.7% | 14.9% | 17.5% |
| Low | 23.1% | 12.8% | 4.8% | -0.7% | 12.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | 6.49 | 7.55 | 8.88 | 9.90 |
| Avg | 4.95 | 6.30 | 7.64 | 8.54 |
| Low | 4.01 | 5.19 | 6.32 | 6.83 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | 68.5% | 52.6% | 40.9% | 29.6% |
| Avg | 28.5% | 27.4% | 21.1% | 11.8% |
| Low | 4.1% | 5.0% | 0.3% | -10.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.